Literature DB >> 14557624

Polyclonal immunoglobulin G from patients neutralizes human immunodeficiency virus type 1 primary isolates by binding free virions, but without interfering with an initial CD4-independent attachment of the virus to primary blood mononuclear cells.

Renaud Burrer1, Sandrine Haessig-Einius, Anne-Marie Aubertin, Christiane Moog.   

Abstract

We investigated the relationship between human immunodeficiency virus type 1 (HIV-1) primary isolate (PI) antibody-mediated neutralization and attachment to primary blood mononuclear cells (PBMC). Incubation of PIs with immunoglobulin G (IgG) purified from infected patients did not inhibit attachment of the viruses with PBMC, but partial to complete neutralization was achieved. Neutralization of PIs already fixed on the cells was achieved by some IgG samples only and was of limited intensity compared to the former neutralization protocol. On the contrary, the binding of IgG to free virions was shown to be sufficient to reach potent neutralization, as the infectivity of IgG-PI complexes purified from the bulk of antibodies before addition to PBMC was strongly diminished compared to mock-treated controls. Monoclonal antibodies to the CDR2 domain of CD4 completely inhibited the infection of PBMC without interfering with the attachment of PIs to the cells, suggesting that, under these experimental conditions, the initial attachment of viruses to PBMC involves alternative cellular receptors. This initial interaction may also involve other components of the viral envelope than gp120, as partial depletion of the surface glycoproteins of primary viral particles that resulted in an almost complete loss of infectivity did not impair attachment to PBMC. A limited inhibition of attachment was observed when interfering with putative interactions with cellular heparan sulfate, whereas no effect was observed for cellular CD147 or nucleolin or for virion-incorporated cyclophilin A. Altogether, our results favor a mechanism of neutralization of HIV-1 PIs by polyclonal IgG where antibodies predominantly bind free virions and neutralize without interfering with the attachment to PBMC, which, in this model, is mainly CD4 independent.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14557624      PMCID: PMC229376          DOI: 10.1128/jvi.77.21.11385-11397.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

1.  Increased infectivity of HIV type 1 particles bound to cell surface and solid-phase ICAM-1 and VCAM-1 through acquired adhesion molecules LFA-1 and VLA-4.

Authors:  Z Liao; J W Roos; J E Hildreth
Journal:  AIDS Res Hum Retroviruses       Date:  2000-03-01       Impact factor: 2.205

2.  Separable mechanisms of attachment and cell uptake during retrovirus infection.

Authors:  S Sharma; A Miyanohara; T Friedmann
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

Review 3.  Neutralizing antibodies against HIV -- back in the major leagues?

Authors:  Flavia Ferrantelli; Ruth M Ruprecht
Journal:  Curr Opin Immunol       Date:  2002-08       Impact factor: 7.486

4.  Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques.

Authors:  Timothy Fouts; Karla Godfrey; Kathryn Bobb; David Montefiori; Carl V Hanson; V S Kalyanaraman; Anthony DeVico; Ranajit Pal
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-21       Impact factor: 11.205

5.  Host cyclophilin A mediates HIV-1 attachment to target cells via heparans.

Authors:  A C Saphire; M D Bobardt; P A Gallay
Journal:  EMBO J       Date:  1999-12-01       Impact factor: 11.598

6.  Differences in affinity of anti-CD4 monoclonal antibodies predict their effects on syncytium induction by human immunodeficiency virus.

Authors:  D Wilks; L Walker; J O'Brien; J Habeshaw; A Dalgleish
Journal:  Immunology       Date:  1990-09       Impact factor: 7.397

7.  The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection.

Authors:  J M Binley; A Trkola; T Ketas; D Schiller; B Clas; S Little; D Richman; A Hurley; M Markowitz; J P Moore
Journal:  J Infect Dis       Date:  2000-08-01       Impact factor: 5.226

8.  Dissociation of gp120 from HIV-1 virions induced by soluble CD4.

Authors:  J P Moore; J A McKeating; R A Weiss; Q J Sattentau
Journal:  Science       Date:  1990-11-23       Impact factor: 47.728

9.  Human immunodeficiency virus Env-independent infection of human CD4(-) cells.

Authors:  S Pang; D Yu; D S An; G C Baldwin; Y Xie; B Poon; Y H Chow; N H Park; I S Chen
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

10.  Novel anti-CD4 monoclonal antibodies separate human immunodeficiency virus infection and fusion of CD4+ cells from virus binding.

Authors:  D Healey; L Dianda; J P Moore; J S McDougal; M J Moore; P Estess; D Buck; P D Kwong; P C Beverley; Q J Sattentau
Journal:  J Exp Med       Date:  1990-10-01       Impact factor: 14.307

View more
  5 in total

1.  Time frames for neutralization during the human immunodeficiency virus type 1 entry phase, as monitored in synchronously infected cell cultures.

Authors:  Hillel Haim; Israel Steiner; Amos Panet
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

2.  Efficient inhibition of HIV-1 replication in human immature monocyte-derived dendritic cells by purified anti-HIV-1 IgG without induction of maturation.

Authors:  Vincent Holl; Maryse Peressin; Sylvie Schmidt; Thomas Decoville; Susan Zolla-Pazner; Anne-Marie Aubertin; Christiane Moog
Journal:  Blood       Date:  2006-02-09       Impact factor: 22.113

3.  Stimulation of HIV-1 replication in immature dendritic cells in contact with primary CD4 T or B lymphocytes.

Authors:  Vincent Holl; Ke Xu; Maryse Peressin; Alexandre Lederle; Marina Elizabeth Biedma; Maryse Delaporte; Thomas Decoville; Sylvie Schmidt; Géraldine Laumond; Anne-Marie Aubertin; Christiane Moog
Journal:  J Virol       Date:  2010-02-10       Impact factor: 5.103

4.  Interactions between natural killer cells and antibody Fc result in enhanced antibody neutralization of human immunodeficiency virus type 1.

Authors:  Donald N Forthal; Gary Landucci; Tran B Phan; Juan Becerra
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

5.  Inhibition of HIV Env binding to cellular receptors by monoclonal antibody 2G12 as probed by Fc-tagged gp120.

Authors:  James M Binley; Stacie Ngo-Abdalla; Penny Moore; Michael Bobardt; Udayan Chatterji; Philippe Gallay; Dennis R Burton; Ian A Wilson; John H Elder; Aymeric de Parseval
Journal:  Retrovirology       Date:  2006-07-03       Impact factor: 4.602

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.